scholarly journals Small-vessel disease in patients with Parkinson's disease: A clinicopathological study

2012 ◽  
Vol 27 (12) ◽  
pp. 1506-1512 ◽  
Author(s):  
Raymond S. Schwartz ◽  
Glenda M. Halliday ◽  
Dennis J. Cordato ◽  
Jillian J. Kril
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Small Vessel Disease ◽  
Small Vessel ◽  
Vessel Disease ◽  
Clinicopathological Study

scholarly journals Influence of Striatal Dopamine, Cerebral Small Vessel Disease, and Other Risk Factors on Age-Related Parkinsonian Motor Signs

2019 ◽  
Vol 75 (4) ◽  
pp. 696-701
Author(s):  
Caterina Rosano ◽  
Andrea L Metti ◽  
Andrea L Rosso ◽  
Stephanie Studenski ◽  
Nicolaas I Bohnen
Keyword(s):  
Risk Factors ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Small Vessel Disease ◽  
Cerebral Small Vessel Disease ◽  
Older Age ◽  
Striatal Dopamine ◽  
Small Vessel ◽  
Vessel Disease ◽  
Age Related

Abstract Objective Parkinsonian motor signs are common and disabling in older adults without Parkinson’s disease (PD), but its risk factors are not completely understood. We assessed the influence of striatal dopamine levels, cerebral small vessel disease, and other factors on age-related parkinsonian motor signs in non-PD adults. Methods Striatal dopamine transporter (DAT) binding was quantified via [11C]-CFT positron emission tomography in 87 neurologically intact adults (20–85 years, 57.47% female) with concurrent data on: Unified Parkinson’s Disease Rating Scale motor (UPDRSm), white matter hyperintensities (WMH), and other risk factors (grip strength, vibratory sensitivity, cardio- and cerebro-vascular comorbidities). Sex-adjusted nonparametric models first estimated the associations of age, DAT, WMH, and other factors with UPDRSm; next, interactions of age by DAT, WMH, or other factors were tested. To quantify the influence of DAT, WMH, and other risk factors on the main association of age with UPDRSm, multivariable mediation models with bootstrapped confidence intervals (CI) were used. Results Older age, lower DAT, higher WMH, and worse risk factors significantly predicted worse UPDRSm (sex-adjusted p < .04 for all). DAT, but not WMH or other factors, positively and significantly interacted with age (p = .02). DAT significantly reduced the age-UPDRSm association by 30% (results of fully adjusted mediation model: indirect effect: 0.027; bootstrapped 95% CI: 0.0007, 0.074). Conclusions Striatal dopamine appears to influence to some extent the relationship between age and parkinsonian signs. However, much of the variance of parkinsonian signs appears unexplained. Longitudinal studies to elucidate the multifactorial causes of this common condition of older age are warranted.

scholarly journals The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis

2021 ◽  
Vol 22 (9) ◽  
pp. 4958
Author(s):  
Federico Paolini Paoletti ◽  
Simone Simoni ◽  
Lucilla Parnetti ◽  
Lorenzo Gaetani
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Small Vessel Disease ◽  
Small Vessel ◽  
Vessel Disease ◽  
Immune System Activation ◽  
The Impact

Brain small vessel disease (SVD) refers to a variety of structural and functional changes affecting small arteries and micro vessels, and manifesting as white matter changes, microbleeds and lacunar infarcts. Growing evidence indicates that SVD might play a significant role in the neurobiology of central nervous system (CNS) neurodegenerative disorders, namely Alzheimer’s disease (AD) and Parkinson’s disease (PD), and neuroinflammatory diseases, such as multiple sclerosis (MS). These disorders share different pathophysiological pathways and molecular mechanisms (i.e., protein misfolding, derangement of cellular clearance systems, mitochondrial impairment and immune system activation) having neurodegeneration as biological outcome. In these diseases, the actual contribution of SVD to the clinical picture, and its impact on response to pharmacological treatments, is not known yet. Due to the high frequency of SVD in adult-aged patients, it is important to address this issue. In this review, we report preclinical and clinical data on the impact of SVD in AD, PD and MS, with the main aim of clarifying the predictability of SVD on clinical manifestations and treatment response.

Progression of small vessel disease correlates with cortical thinning in Parkinson’s disease

2016 ◽  
Vol 31 ◽  
pp. 34-40 ◽  
Author(s):  
Heidi Foo ◽  
Elijah Mak ◽  
Ting Ting Yong ◽  
Ming-Ching Wen ◽  
Russell Jude Chander ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Small Vessel Disease ◽  
Small Vessel ◽  
Cortical Thinning ◽  
Vessel Disease

Effect of small vessel disease burden and lacunes on gait/posture impairment in Parkinson’s disease

2020 ◽  
Vol 41 (12) ◽  
pp. 3617-3624
Author(s):  
Huimin Chen ◽  
Meimei Zhang ◽  
Gengliang Liu ◽  
Xuemei Wang ◽  
Zhan Wang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Burden ◽  
Small Vessel Disease ◽  
Small Vessel ◽  
Vessel Disease ◽  
Gait Posture

Impact of small vessel disease on severity of motor and cognitive impairment in Parkinson’s disease

2018 ◽  
Vol 58 ◽  
pp. 70-74 ◽  
Author(s):  
Raymond S. Schwartz ◽  
Glenda M. Halliday ◽  
Derrick Soh ◽  
Dennis J. Cordato ◽  
Jillian J. Kril
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Small Vessel Disease ◽  
Small Vessel ◽  
Vessel Disease

scholarly journals Total Cerebral Small Vessel Score Association With Hoehn and Yahr Stage in Parkinson’s Disease

2021 ◽  
Vol 13 ◽  
Author(s):  
Xinxin Ma ◽  
Shuhua Li ◽  
Chunmei Li ◽  
Rui Wang ◽  
Min Chen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Small Vessel Disease ◽  
Critical Role ◽  
Multivariate Logistic Regression Analysis ◽  
Brain Magnetic Resonance Imaging ◽  
Small Vessel ◽  
Perivascular Spaces ◽  
Related Factors ◽  
Multiple Variables

Background: This study aimed to evaluate the total cerebral small vessel disease (CSVD) score in patients with Parkinson’s disease (PD) at different stages and related factors.Methods: A 100 and seven patients with idiopathic PD and 62 normal controls (NCs) who underwent brain magnetic resonance imaging (MRI) were enrolled. PD patients were divided into two groups: early PD [(Hoehn and Yahr (H&Y) 1–1.5, n = 36)] and advanced PD (H&Y 2–4, n = 71) groups. We calculated the total CSVD score for each participant based on lacunes, high-grade white matter hyperintensities (WMH), enlarged perivascular spaces (EPVS), and cerebral microbleeds (CMBs). Differences in total CSVD score between the PD and NCs and between the two subgroups were compared. In addition, a multivariate logistic regression analysis was conducted to investigate the association between CSVD markers and clinical variables in PD.Results: Lacunes were found in 9.3% of patients with PD, periventricular WMH (PVWMH) in 89.7%, deep WMH (DWMH) in 81.3%, EPVS in 85%, and CMBs in 2.8%. Compared with NCs, patients with PD showed higher PVWMH and DWMH scores. Advanced PD patients exhibited greater PVWMH (P = 0.041), DWMH (P = 0.046), and total CSVD score (P = 0.044) than the early PD group. After adjusting for multiple variables, higher H&Y stage was independently correlated with increased total CSVD score (OR = 2.667, 95% CI 1.154–2.266) and PVWMH score (OR = 2.237, 95% CI 1.084–1.696).Conclusions: CSVD may play a critical role in patients with PD. The total CSVD score is a potential neuroimaging marker for monitoring the progression of PD.

Sign in / Sign up

Export Citation Format

Share Document